CDX-301

Generic Name: CDX-301

Clinical Trials

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Phase 1

Recruiting

Conditions: HER2-negative Breast Cancer
Metastatic Breast Cancer

Interventions: Drug: PLD Chemotherapy
Drug: CDX-1140
Drug: CDX-301

First Posted Date: 2021-09-01

Last Posted Date: 2025-05-16

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 30

Registration Number: NCT05029999

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States

and more 4 locations

The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.

Phase 1

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Biological: PGV-001
Biological: Poly-ICLC
Biological: CDX-301

First Posted Date: 2021-08-18

Last Posted Date: 2024-10-28

Lead Sponsor: Ashutosh Kumar Tewari

Target Recruit Count: 27

Registration Number: NCT05010200

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai (ISMMS), New York, New York, United States

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

Phase 1

Recruiting

Conditions: Metastatic Melanoma
Melanoma

Interventions: Drug: CDX-301
Biological: NEOVAX
Drug: Nivolumab
Drug: Pembrolizumab

First Posted Date: 2021-06-18

Last Posted Date: 2025-03-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT04930783

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients

Phase 2

Terminated

Conditions: Pancreatic Cancer
Cancer of the Pancreas
Pancreas Cancer

Interventions: Drug: CDX-1140
Drug: CDX-301
Procedure: Research blood draw

First Posted Date: 2020-09-02

Last Posted Date: 2024-10-08

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 16

Registration Number: NCT04536077

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Converting HR+ Breast Cancer Into an Individualized Vaccine

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Radiation: Focal Radiation therapy
Biological: CDX-301
Drug: Pembrolizumab (200mg IV for 30 minutes

First Posted Date: 2019-01-15

Last Posted Date: 2025-02-19

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 100

Registration Number: NCT03804944

Locations: 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
Brooklyn Methodist Hospital - NewYork Presbyterian, New York, New York, United States
🇺🇸
Weill Cornell Medicine New York Presbyterian Hospital, New York, New York, United States

and more 5 locations

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Breast Cancer
Gastric Cancer
Fallopian Tube Cancer
Other Solid Tumors
Indolent B-cell Lymphomas
Waldenstrom's Disease
Marginal Zone Lymphoma
Pancreatic Adenocarcinoma
Esophageal Cancer
Primary Peritoneal Cancer

Interventions: Drug: CDX-1140
Drug: CDX-301
Drug: Chemotherapy
Drug: pembrolizumab

First Posted Date: 2017-11-06

Last Posted Date: 2024-03-28

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 132

Registration Number: NCT03329950

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Houston Methodist, Houston, Texas, United States
🇺🇸
Northside Hospital, Inc., Atlanta, Georgia, United States

and more 8 locations

A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs

Phase 2

Terminated

Conditions: For Donors
Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling
For Recipients
Acute Myelogenous Leukemia (AML)
Acute Lymphoblastic Leukemia (ALL)
Myelodysplastic Syndrome (MDS)
Chronic Myelogenous Leukemia (CML)
Non-Hodgkins Lymphoma (NHL)
Hodgkins Disease (HD)
Chronic Lymphocytic Leukemia (CLL)

Interventions: Drug: CDX-301
Drug: CDX-301 and plerixafor

First Posted Date: 2014-07-25

Last Posted Date: 2017-04-07

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 36

Registration Number: NCT02200380

Locations: 🇺🇸
Emory University-Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸
University of Iowa, Iowa City, Iowa, United States

and more 5 locations

A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CDX-301

First Posted Date: 2011-11-04

Last Posted Date: 2017-06-27

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 30

Registration Number: NCT01465139

Locations: 🇺🇸
Rockefeller University, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy